

Supporting Information

for

**Autonomous assembly of synthetic oligonucleotides built
from an expanded DNA alphabet. Total synthesis of a gene
encoding kanamycin resistance**

Kristen K. Merritt^{1,2}, Kevin M. Bradley^{1,2}, Daniel Hutter^{1,2,3}, Mariko F. Matsuura^{1,2,4}, Diane J. Rowold^{1,2},
and Steven A. Benner^{1,2,3*}

Address: ¹Foundation for Applied Molecular Evolution, P.O. Box 13174, Gainesville, FL, 32604, ²The Westheimer Institute for Science and Technology, 720 S. W. 2nd Avenue, Suites 201-208, Gainesville, FL, 32601, ³Firebird Biomolecular Sciences LLC, 13709 Progress Blvd. Box 17, Alachua, FL 32615 and ⁴Department of Chemistry, University of Florida, Gainesville, FL, 32611

Email: Steven A. Benner - sbenner@firebirdbio.com

* Corresponding author

Additional Information

Fragment design for three “push to fail” constructs

In independent experiments (and in two different physical locations), three of the coauthors attempted the autonomous assembly of three long-DNA (L-DNA) constructs from synthetic DNA fragments designed by the OligArch software tool [2]. All three constructs were designed to have approximately 1100 nucleobase pairs and arise via self-assembly of 32 single stranded DNA fragments (see **Figures S1, S2 and S3** and **Tables S7, S8, and S9**). The target constructs had no function at all which allowed their designs to have, as their only goal, successful autonomous self-assembly. OligArch generated these three sets of sequences by using three different “seeds” to initiate the fragment design.

The 32 fragments were designed by the OligArch software to have nearly identical lengths (50-52 nts) with 15-17 nucleotide overlaps having melting temperatures predicted to lie in a narrow range (44 - 56 °C). The sequences were programmed to form no-off target hybrids having a melting temperature greater than 25 °C, a full 20 °C below that predicted for the desired annealing pairs. Two of the three constructs (“32B” and “32C”) contained only the four standard nucleotides, G, A, T, and C. In the third construct (“32A”), OligArch placed AEGIS nucleotides S and B (**Figure 2** of the principal manuscript) in the overlapping regions to facilitate self-assembly. **Figures S1, S2, and S3** show the designed oligonucleotides aligned to show their hybridizing segments. The gaps were subsequently filled in by DNA polymerase to yield nicked constructs, and the nicks were sealed by ligase.

Annealing extension and ligation

The oligonucleotide fragments were prepared by automated DNA synthesis and quantitated by UV spectroscopy. The oligonucleotides used for 32B and 32C constructs were ordered from Integrated DNA Technologies (IDT, Coralville, IA, USA). The oligonucleotides used for 32A

construct were ordered from Firebird Biomolecular Sciences (Gainesville, FL, USA). Self-assemblies of constructs were attempted in stages by annealing, extension and ligation (AEL) of various subsets of the total fragment set as outlined below.

(a) Annealing: An annealing solution (40 μ L) was prepared by mixing equal concentrations of each synthetic oligonucleotide (1 μ L of 20 μ M unless otherwise stated) and 1X ISO reaction buffer (5% PEG-8000, 100 mM Tris-HCl, pH 7.5, 10 mM $MgCl_2$, 10 mM DTT, 1 mM NAD^+). The mixture was then heated to 80 $^{\circ}C$ for 5 min, and the temperature was then reduced at 0.1 $^{\circ}C/sec$ to 40 $^{\circ}C$ (32C/32B) or 42 $^{\circ}C$ for 30 minutes (32A).

(b) Extension and ligation: Unless otherwise stated, the extension and ligation proceeded as follows: An enzyme mixture (15 μ L) was created in 1X ISO reaction buffer (5% PEG-8000, 100 mM Tris-HCl, pH 7.5, 10 mM $MgCl_2$, 10 mM DTT, 1 mM NAD^+) with 0.05 U/ μ L Phusion[®] High-Fidelity DNA Polymerase, 2.0 U/ μ L *Taq* DNA Ligase, and 0.2 mM dNTPs. This mixture was added to annealed sample (5 μ L). Then samples were incubated at 40 $^{\circ}C$ for 30 min (32C/32B) or 48 $^{\circ}C$ for 60 minutes (32A).

Downstream analysis:

(a) PCR amplification: To analyze the success of the assemblies of subsets and full sets of the synthetic fragments, PCR was performed with the appropriate primers (**Tables S10, S11 and S12**) in reaction mixtures (50 μ L) containing 1X *Taq* buffer (10 mM Tris-HCl (pH 8.3), 50 mM KCl, 1.5 mM $MgCl_2$), 0.2 mM dNTPs, 0.4 μ M forward/reverse primer sets, and 0.04 U/ μ L *Taq* polymerase) and 1 μ L of the (putatively) ligated oligonucleotides. The following cycling conditions were used: for the 32C/32B constructs, 95 $^{\circ}C$ for 1 minute, followed by 30 cycles of 95 $^{\circ}C$ for 20 seconds, 50 $^{\circ}C$ for 20 seconds, and 72 $^{\circ}C$ for 90 seconds; for the 32A construct, 95 $^{\circ}C$ for 2 minutes, followed by 30 cycles of 95 $^{\circ}C$ for 30

seconds, 55 °C for 20 seconds, and 72 °C for 2 minutes, with a final extension of 72 °C for 10 minutes. The 32A construct containing **S:B** pairs was PCR amplified under conversion conditions with a small amount of **dBTP**, as described in the principal publication. The conversion product was directly cloned and sequenced.

(b) Nucleotide electrophoresis/gel extraction: Primary PCR products as well as secondary PCR amplicons of 16-fragment L-DNA assemblies were analyzed by agarose gel electrophoresis in TAE or TBE buffer (100 V for 20 min (50 V for 60 min for a gel extraction)). In the 32A and 32B constructs, the expected sized bands were cut and transferred to microcentrifuge tubes by shadow visualization under long wave UV (blue light for a gel extraction). A gel extraction was performed by using Zymoclean™ Gel DNA Recovery Kit.

(c) Sanger sequencing: Either purified (QiaQuick from Qiagen) primary PCR amplicon (32C), secondary PCR product from a ligation of gel-purified PCR amplified sub-assemblies (32B; see below for more detail on secondary ligation), or cloned, PCR converted (**S:B** to **T:A**) full-length construct (32A) was sequenced (Big Dye v 3.1, Life Technologies) as per vendor instructions and analyzed via capillary-based automated DNA sequencing at an offsite facility (the Interdisciplinary Center for Biotechnology Research (ICBR) of University of Florida, Gainesville, FL, USA).

PCR and ligation of sub-assemblies (32B construct): Since PCR amplification failed to detect any product from autonomous self-assembly of all 32 fragments together of the 32B construct (**Figure 8** of manuscript), the products of the two 16-fragment sub-assemblies were each PCR amplified, using 50 µL of the same reaction mixture and 0.5 µL of the primary PCR products. A reaction mixture (20 µL, 1X T4 DNA Ligase Buffer, 20 U/mL

T4 DNA Ligase (New England Biolabs) with added oligonucleotides (gel extracted 16-fragment assemblies, 50 ng each) was prepared in a microcentrifuge tube on ice. The reaction was incubated for two hours at room temperature and the completed ligation reaction of 32-fragment assemblies was PCR amplified. Amplicons were loaded on an agarose gel (1%) and separated in TAE buffer with 100 V for 30 minutes (**Figure S4**).

Results and Conclusions

When AEGIS nucleotides were used to assist annealing, a full-length product was obtained in the first try by PCR amplification of the AEL construct (**Figure 7** of manuscript). This was not necessarily the case when comparable attempts were made from the constructs using only standard nucleotides (32B and 32C) as discussed below (manuscript **Figure 8**, **Figure S4** and **Figure S5**).

No full-length AEL product was observed when all 32 fragments of the 32B set were mixed (last lane, **Figure 8**). To rule out the possibility that the oligonucleotides were defective, smaller constructs were self-assembled. **Figure 8** shows the results of stepwise assembly of sub-sets of the fragments, after the target ligation products are rescued from the mixture by PCR (30 cycles). Attempts to assemble 20, 24, 28, and 32 fragments failed to yield any detectable amplicon. Products arising from self-assembly of 4, 8 and 16 could be recovered by PCR in decreasing yields (**Figure 8**).

An alternate strategy was to independently assemble and PCR amplify the two halves (oligos #1 to 16 and oligos #17 to 32) of the 32B construct. This created half assemblies in large amounts, which then could be ligated with blunt ends. The desired 1135 base pair target construct was then recovered by PCR (**Figure S4**). This process, which represents the same

stepwise convergent assembly of L-DNA that has been used previously [3-5][6], of course, is not automated.

Autonomous self-assembly of multiple single stranded fragments can fail for many “trivial” reasons. Simplest among these is the fact that single stranded folding (e.g., to give hairpins) can compete with intermolecular hybridization (**Figure 1**). Hairpin formation (**Figure S6**) may have contributed to the failure of the 32B assemblies involving 20 or more oligonucleotides (**Figure 8 of principal manuscript**). Since single stranded hybridization is a unimolecular process, the rate of folding and the corresponding equilibrium constant are independent of the concentration of the oligonucleotide. Thus, it competes more effectively with desired bimolecular hybridizations when the concentrations of the DNA fragments are low, an easy outcome when attempting to autonomously assembly many fragments.

Hairpins with short stems are, of course, impossible to avoid. For example, the 3'-end of a standard oligonucleotide must be G, A, C, or T; it must therefore find a partner with a 25% probability to form a hairpin having a loop of any arbitrary length with a single base pair in the stem. Likewise, any dinucleotide has a 6% probability of forming a hairpin having a loop of any arbitrary length with a two base pair stem.

The 32C assembly attempt also failed at first. Successful self-assembly of 32 fragments built from standard nucleotides was identified only once; after multiple tries and only after increasing the AEL concentrations of oligonucleotide fragments from 62.5 nM to 125 nM could a PCR product of the desired length be recovered (**Figure S5**). While general conclusions are difficult to draw from these experiments alone, it appears that addition of AEGIS nucleotides to procedures that synthesize L-DNA constructs advances further the performance of automated and semi-automated gene synthesis.

Table S1: Selected sequences of kanamycin resistance gene assembled using AEGIS S:B pairs obtained from *E. coli* displaying resistance to kanamycin

* indicates a site where none of the sequences displayed an error

KanR_AEGIS	CTAGTGGSCGBTCTGSCCGTCCTGTCAGCTGCTGSCGSGCGGATCCTG	50
KanR_normal	-----	1
Kan09 with dBTP	-----GTCCGACCTGTCAGCTGCTAGTCGTGCGGATCCTG	36
Kan11 with dBTP	-----GTCCGTCCTGTCAGCTGCTAGTCGTGCGGATCCCG	36
Kan14 with dBTP	-----GTCCGTCAGCTGCTATTCGGGGGGATCCTG	32
KanR_AEGIS	TTAGAAAACTCATCGAGCATCAAATGAAACTGCAA*TT*TTTCAT*TC*GG	100
KanR_normal	TTAGAAAACTCATCGAGCATCAAATGAAACTGCAATTTATTCATATCAGG	51
Kan09 with dBTP	TCAGAAAACTCATCGAGCATCAAATGAAACTGCAATTTGTTTCATATCCGG	86
Kan11 with dBTP	TTAGAAAACTCATCGAGCATCAAATGAAACTGCAATTTATTCATATCAGG	86
Kan14 with dBTP	TTAGATCC*-TTTCATCGAGCATCATATGAAACTGCAATTTATTCATATCAGG	81

KanR_AEGIS	ATTATCAATACCATATTTTTGAAAAAGCCG*STTCTGTAA*SGA*GGAGAAA	150
KanR_normal	ATTATCAATACCATATTTTTGAAAAAGCCGTTTCTGTAAATGAAGGAGAAA	101
Kan09 with dBTP	ATTATCAATACCATATTTTTGAAAAAGCCGTTTCTGTAAATGAAGGA*CAAA	136
Kan11 with dBTP	ATTATCAATACCATATTTTTGAAAAAGCCGTTTCTGTAAATGAAGGAGAAA	136
Kan14 with dBTP	ATTATCAATACCATATTTTTGAAAAAGC*TTT*TTCTGCAATGACCCGA*AAA	131
Kan12 without dBTP	ATTATCAATACCATATTTTTGAAAAAGCCGTTTCTGTAAATGAAGGAGAAA	136
Kan13 without dBTP	ATTATCAATACCATATTTTTGAAAAAGCCG*CTTCTGTAAATGAAGGAGAAA	136

KanR_AEGIS	ACTCACCGAGGCAGTTCCATAGGATGGC*AG*TCCTGGTA*SCGGTCTGCG	200
KanR_normal	ACTCACCGAGGCAGTTCCATAGGATGGCAAGATCCTGGTATCGGTCTGCG	151
Kan09 with dBTP	ACTCACCGAGGCAGTTCCATAGGATGGCAAGATCCTGGTATCGGTCTGCG	186
Kan11 with dBTP	ACTCACCGAGGCAGTTCCATAGGATGGCAAGATCCTGGTATCGGTCTGCG	186
Kan14 with dBTP	ACTCACCGAGGCAGTTCCATAGGATGGCAAGATCCTGGTATCGGTCTGCG	181

KanR_AEGIS	ATTCCGAC*SCG*SCC*AC*TCATAACAACCTATTAATTCCCCTCGTCAAA	250
KanR_normal	ATTCCGACTCGTCCAACATCAATACAACCTATTAATTCCCCTCGTCAAA	201
Kan09 with dBTP	ATTCCGACTCGTCCAACATCAATACAACCTATTAATTCCCCTCGTCAAA	236
Kan11 with dBTP	ATTCCGACTCGTCCAACATCAATACAACCTATTAATTCCCCTCGTCAAA	236
Kan14 with dBTP	ATTCCGACTCGTCCAACATCAATACAACCTATTA-TTCCCCTCGTCAAA	230

KanR_AEGIS	AATAAGGTT*TC*AG*SGAGAA*TCACCATGAGTGACGACTGAATCCGGTG	300
KanR_normal	AATAAGGTTATCAAGTGAGAAATCACCATGAGTGACGACTGAATCCGGTG	251
Kan09 with dBTP	AATAAGGTTATCAAGTGAGAAATCACCATGAGTGACGACTGAATCCCGTG	286
Kan11 with dBTP	AATAAGGTTATCAAGTGAGAAATCACCATGAGTGACGACTGAATCCGGTG	286
Kan14 with dBTP	AATAAGGTTATCAAGAGAGAAATC*CCATGAGTGACGACTGAAT*TTGTA	280

KanR_AEGIS	AGAA*SGCAA*AG*STT*TGCAATTCCTTTCCAGAC*STG*STC*AC*GGCCAG	350
KanR_normal	AGAATGGCAAAAGTTTATGCATTTCTTTCCAGACTTGTTCAACAGGCCAG	301
Kan09 with dBTP	AGAATGGCAAAAGTTTATGCATTTCTTTCCAGACTTGTTCAACAGGCCAG	336
Kan11 with dBTP	AGAATGGCAAAAGTTTATGCATTTCTTTCCAGACTTGTTCAACAGGCCAG	336
Kan14 with dBTP	AGAATGGCAAAAGTTTATGCATTTCTTTCCAGACTTGATCAACAGGCCAG	330

KanR_AEGIS	CCATTACGCTCGTCATCAAAATCACTCGC*TC*ACCAA*CCGTTATTTCAT	400
KanR_normal	CCATTACGCTCGTCATCAAAATCACTCGCATCAACCAAACCGTTATTTCAT	351
Kan09 with dBTP	CCATTACGCTCGTCATCAAAATCACTCGCATCAACCAA*CCGTTATTTCAT	386
Kan11 with dBTP	CCATTACGCTCGTCATCAAAATCACTCGCATCAACCAAACCGTTATTTCAT	386
Kan14 with dBTP	CCATTACGCTCGTCATCAAAATCACTCGCATCAACCAA*CCGTTATTTCAT	380

KanR_AEGIS	TCGTGATTGCGCCTG*GCGAG*CGAAATACGCGATCGCTGTTAAAGGAC	450
KanR_normal	TCGTGATTGCGCCTGAGCGAGACGAAATACGCGATCGCTGTTAAAGGAC	401
Kan09 with dBTP	TCGTGATTGCGCCTGAGCGAGACGAAATACGCGATCGCTGTTAAAGGAC	436
Kan11 with dBTP	TCGTGATTGCGCC*CGAGCGAGACGAAATACGCGATCGCTGTTAAAGGAC	436
Kan14 with dBTP	TCGTGATTGCGCCTGAGCGAGACGAAATACGCGATCGCTGTTAAAGGAC	430

KanR_AEGIS	AATTAC*AAAC*GGAATCGA*TGCAACCGGCGCAGGAACACTGCCAGCGCA	500
KanR_normal	AATTACAAACAGGAATCGAATGCAACCGGCGCAGGAACACTGCCAGCGCA	451
Kan09 with dBTP	AATTACAAACAGGAATCGAATGCAACCGGCGCAGGAACACTGCCAGCGCA	486
Kan11 with dBTP	AATTACAAACAGGAATCGAATGCAACCGGCGCAGGAACACTGCCAGCGCA	486
Kan14 with dBTP	AATTACAAACAGGAATCGAATGCAACCGGCGCAGGAACACTGCCAGCGCA	480

```

*****
KanR_AEGIS      TCACAATBTSTCCCTGAATCAGGATATTCTTCTAATACCTGGAASGC 550
KanR_normal     TCAACAATATTTTCACCTGAATCAGGATATTCTTCTAATACCTGGAATGC 501
Kan09 with dBTP TCAACAATATTTTCACCTGAATCAGGATATTCTTCTAATACCTGGAATGC 536
Kan11 with dBTP TCAACAATATTTTCACCTGAATCAGGATATTCTTCTAATACCTGGAATGC 536
Kan14 with dBTP TCAACAATATTTTCACCTGAATCAGGATATTCTTCTAATACCTGGAATGC 530
*****

KanR_AEGIS      SGTSTTSCCGGGGATCGCAGTGGTGAGTAACCATGCATCBTCGGGTGC 600
KanR_normal     TGTTTTTCCGGGGATCGCAGTGGTGAGTAACCATGCATCATCAGGAGTAC 551
Kan09 with dBTP TGTTTTTCCGGGGATCGCAGTGGTGAGTAACCATGCATCATCAGGAGTAC 586
Kan11 with dBTP TGTTTTTCCGGGGATCGCAGTGGTGAGTAACCATGCATCATCAGGAGTAC 586
Kan14 with dBTP TGTTTTTCCGGGGATCGCAGTGGTGAGTAACCATGCATCATCAGGAGTAC 580
*****

KanR_AEGIS      GGATAAAATGCTTGATGGTCGGAGGGCATAAASTCCGTCAGCCAGTTT 649
KanR_normal     GGATAAAATGCTTGATGGTCGGAAGAGGCATAAAATCCGTCAGCCAGTTT 600
Kan09 with dBTP GGATAAAATGCTTGATGGTCGGAAGAGGCATAAAATCCGTCAGCCAGTTT 635
Kan11 with dBTP GGATAAAATGCTTGATGGTCGGAAGAGGCATAAAATCCGTCAGCCAGTTT 635
Kan14 with dBTP GGATAAAATGCTTGATGGTCGGAAGAGGCATAAAATCCGTCAGCCAGTTT 629
*****

KanR_AEGIS      AGTCTGACCATCTCATCTGTACBTCATTGGCAECGTACCTTTGCCATG 698
KanR_normal     AGTCTGACCATCTCATCTGTAAACATCATTTGGCAACGCTACCTTTGCCATG 649
Kan09 with dBTP AGTCTGACCATCTCATCTGTAAACATCATTTGGCAACGCTACCTTTGCCATG 684
Kan11 with dBTP AGTCTGACCATCTCATCTGTACATCATTTGGCAACGCTACCTTTGCCATG 684
Kan14 with dBTP AGTCTGACCATCTCATCTGTAAACATCATTTGGCACGCTACCTTTGCCATG 678
*****

KanR_AEGIS      TTTCAGAAACAACCTSGGCGCTCGGGCTTCCCATACAAGCGATAGATTG 744
KanR_normal     TTTCAGAAACAACCTCTGGCGCATCGGGCTTCCCATACAAGCGATAGATTG 695
Kan09 with dBTP TTTCAGAAACAACCTCGGCGCATCGGGCTTCCCATACAAGCGATAGATTG 730
Kan11 with dBTP TTTCAGAAACAACCTCTGGCGCATCGGGCTTCCCATACAAGCGATAGATTG 730
Kan14 with dBTP TTTCAGAAACAACCTCTGGCGCATCGGGCTTCCCATACAAGCGATAGATTG 724
*****

KanR_AEGIS      TCGCACCSGASTGCCCGACBTATCGCGAGCCCATTTATACCCATATAAA 786
KanR_normal     TCGCACCTGATTGCCCGACATTATCGCGAGCCCATTTATACCCATATAAA 737
Kan09 with dBTP TCGCACCTGATTGCCCGACATTATCGCAAGCCCATTTATACCCATATAAA 772
Kan11 with dBTP TCGCACCTGATTGCCCGACATTATCGCGAGCCCATTTATACCCATATAAA 772
Kan14 with dBTP TCGCACCTGATTGCCCGACATTATCGCGAGCCCATTTATACCCATATAAA 766
*****

KanR_AEGIS      TCAGCTCCATGTTGGAATTTAATCGCGGCCCTCGACGTTTCCCGTTGAAT 827
KanR_normal     TCAGCATCCATGTTGGAATTTAATCGCGGCCCTCGACGTTTCCCGTTGAAT 778
Kan09 with dBTP TCAGCATCCATGTTGGAATTTAATCGCGGCCCTCGACGTTTCCCGTTGAAT 813
Kan11 with dBTP TCAGCTCCATGTTGGAATTTAATCGCGGCCCTCGACGTTTCCCGTTGAAT 813
Kan14 with dBTP TCAGCATCCATGTTGGAATTTAATCGCGGCCCTCGACGTTTCCCGTTGAAT 807
*****

KanR_AEGIS      ATGGCTCATGGTG
KanR_normal     ATGGCTCAT---
Kan09 with dBTP ATGGCTCATGGTG
Kan11 with dBTP ATGGCTCATGGTG
Kan14 with dBTP ATGGCTCATGGTG
*****

```

Representative sequences of the antisense strand of various gene encoding kanamycin resistance, determined by classical Sanger sequencing from a plasmid prepped from transformed cells grown in the presence of kanamycin. The PCR primer is underlined, not bold. The start sequence in the gene (**CAT**, antisense) is bold underlined. Top line shows the putative construct, including the **S** and **B** nucleotides used to provide controlled orthogonal assembly of the ML-DNA construct. The second line shows the sequence of the native gene encoding the kanamycin resistance protein. The conversion that generated these sequences was done with a small amount of dBTP, requiring only that dTTP mismatch dB in the template. The sequencing results have the expected features, in particular, the loss of quality towards the end of the read. These results show that conversion of S to T and B to A was no less faithful than the sequences obtained generally, which include PCR and sequencing error.

Table S2: Master Mix for conversion PCR

Item	Per reaction	Master Mix (x5)
Taq Full Buffer, 10x	5 μ L	25 μ L
dNTP (stock 10 mM)	1 μ L	5 μ L
KanR For primer (stock 10 μ M)*	2 μ L	10 μ L
KanR Rev primer (stock 10 μ M)*	2 μ L	10 μ L
Taq Full polymerase	0.4 μ L	2.0 μ L
Water	37.6 μ L	188 μ L
Template (DNA or water)	2 μ L	-----
disoGTP (dB)	0.3 or 0 μ L	-----
Total Volume	50 or 50.3 μ L	

*KanR For: CACCATGAGCCATATTCAACGG

*KanR Rev: GTCCGTCCTGTCAGCTGC

Table S3. Secondary PCR recipe and setup

Item	Per reaction	Master Mix (x4)
5X PrimeSTAR GXL	10 μ L	40 μ L
dNTP (10 mM)	1 μ L	4 μ L
KanR For primer (10 μ M)	1.5 μ L	6 μ L
KanR Rev primer (10 μ M)	1.5 μ L	6 μ L
PrimeSTAR polymerase	1 μ L	4 μ L
Water	34 μ L	136 μ L
Template (DNA or water)	1 μ L	-----

Analysis of all sequences of kanamycin resistance gene assembled using AEGIS S:B pairs

Sequences obtained:

Table S4 summarizes the sequences obtained from a series of plasmid preps obtained from *E. coli* before selecting for kanamycin resistance. The “status” was determined by looking at both the upstream and downstream sequencing for a submission and determining if the entire gene was present (Full), if no gene was present (Missing), if there was an incomplete assembly (Incomplete), or if the status could not be determined (?), the last arising from failure in either the upstream or downstream sequencing.

Table S4: Analysis of *E. coli* plasmid prep sequences without selection for resistance

Query	Q. Start	Q. End	S. Start	S. End	Strand	Q. Size	Length	Status
KRplus20_T7Term.ab1	140	986	850	1	Minus	1066	847	Full
KRplus20_T7Long.ab1	77	924	1	850	Plus	1237	848	Full
KRplus19_T7Term.ab1	141	799	850	192	Minus	799	659	Full
KRplus19_T7Long.ab1	80	917	1	839	Plus	920	838	Full
KRplus18_T7Term.ab1	140	637	850	352	Minus	637	498	?
KRplus17_T7Term.ab1	163	645	1	482	Plus	645	483	Full
KRplus17_T7Long.ab1	79	839	850	91	Minus	842	761	Full

KRplus15_T7Term.ab1	141	878	850	115	Minus	881	738	Full
KRplus15_T7Long.ab1	60	912	1	850	Plus	1128	853	Full
KRplus14_T7Term.ab1	141	993	850	1	Minus	997	853	Full
KRplus14_T7Long.ab1	78	929	1	851	Plus	995	852	Full
KRplus13_T7Term.ab1	143	675	1	534	Plus	680	533	Full
KRplus13_T7Long.ab1	75	923	850	1	Minus	1230	849	Full
KRplus12_T7Term.ab1	141	920	850	73	Minus	920	780	Full
KRplus12_T7Long.ab1	63	911	1	850	Plus	1155	849	Full
KRplus11_T7Long.ab1	61	709	1	650	Plus	716	649	?
KRplus10_T7Term.ab1							1	Missing
KRplus10_T7Long.ab1							0	Missing
KRplus09_T7Long.ab1							0	Missing
KRplus08_T7Term.ab1	142	989	850	4	Minus	1069	848	Full
KRplus08_T7Long.ab1	75	924	1	850	Plus	1164	850	Full
KRplus07_T7Term.ab1	162	1016	857	4	Minus	1062	855	Full
KRplus07_T7Long.ab1	63	880	1	815	Plus	880	818	Full
KRplus06_T7Term.ab1	139	755	850	228	Minus	755	617	?
KRplus05_T7Long.ab1							0	Missing
KRplus04_T7Term.ab1	141	594	1	454	Plus	597	454	Full
KRplus04_T7Long.ab1	76	876	850	48	Minus	878	801	Full
KRplus03_T7Term	141	639	850	352	Minus	639	499	Full
KRplus03_T7Long.ab1	77	877	1	802	Plus	879	801	Full
KRplus02_T7Term	139	687	850	303	Minus	687	549	Full
KRplus02_T7Long	96	594	1	500	Plus	594	499	Full
KRplus01_T7Term	140	624	1	486	Plus	624	485	Full
KRplus01_T7Long.ab1	74	922	850	1	Minus	1151	849	Full
KRmin_19_T7Term.ab1	141	951	850	42	Minus	957	811	Full
KRmin_19_T7Long.ab1	63	913	1	850	Plus	1031	851	Full
KRmin_18_T7Term.ab1	140	555	1	415	Plus	555	416	Incomplete
KRmin_18_T7Long.ab1	76	601	526	1	Minus	639	526	Incomplete
KRmin_17_T7Long.ab1	78	681	850	247	Minus	681	604	?
KRmin_16_T7Long.ab1							0	Missing
KRmin_15_T7Term.ab1	156	679	526	1	Minus	760	524	Incomplete
KRmin_13_T7Term.ab							0	Missing

1								
KRmin_13_T7Long.ab 1							0	Missing
KRmin_12_T7Term.ab 1	142	667	1	526	Plus	798	526	Incomplete
KRmin_12_T7Long.ab 1	79	604	526	1	Minus	881	526	Incomplete
KRmin_11_T7Term.ab 1	141	665	1	526	Plus	757	525	Incomplete
KRmin_11_T7Long.ab 1	77	601	526	1	Minus	847	525	Incomplete
KRmin_10_T7Term.ab 1							0	Missing
KRmin_09_T7Term.ab 1	140	986	850	1	Minus	994	847	Full
KRmin_09_T7Long.ab 1	85	803	1	716	Plus	803	719	Full
KRmin_08_T7Term.ab 1	141	666	1	526	Plus	676	526	Incomplete
KRmin_08_T7Long.ab 1	77	602	526	1	Minus	1234	526	Incomplete
KRmin_06_T7Term.ab 1	145	641	1	498	Plus	641	497	Incomplete
KRmin_06_T7Long.ab 1	76	598	526	1	Minus	915	523	Incomplete
KRmin_05_T7Term.ab 1	143	957	1	815	Plus	957	815	Full
KRmin_05_T7Long.ab 1	77	930	850	1	Minus	965	854	Full
KRmin_04_T7Term.ab 1	143	760	1	616	Plus	763	618	Full
KRmin_04_T7Long.ab 1	77	922	850	4	Minus	1025	846	Full
KRmin_03_T7Term.ab 1							0	Missing
KRmin_03_T7Long.ab 1							0	Missing
KRmin_02_T7Term.ab 1	142	665	1	526	Plus	801	524	Incomplete
KRmin_02_T7Long.ab 1	76	599	526	1	Minus	915	524	Incomplete
KRmin_01_T7Term.ab 1							0	Missing
KRmin_01_T7Long.ab 1							0	Missing

As a breakdown of the above information, the counts for each category of gene completeness are shown in Table S5.

Table S5: Summary of completeness in self-assembled kanamycin resistance gene

Gene Status	Count
Full	17
Incomplete Assembly	7
Missing	8
Unknown (?)	4

No incomplete assemblies were found when dBTP was used in the conversion PCR; 13 full assemblies were found under these conditions. This can be compared to 7 incomplete assemblies found when dBTP was absent in the conversion PCR; here, only 4 full assemblies.

Error in self-assembled kanamycin resistance gene:

Table S6 compares errors in this set of sequencing results to a set of 31 sequences obtained from cultured *E. coli* shown to have resistance to kanamycin (full data not shown; selection shown in **Table S1**). This comparison shows no appreciable increase in errors due to conversion between sequences conferring kanamycin resistance and all amplified sequences. Locations that underwent conversion from AEGIS bases had slightly higher error rates than those that did not. The overall rate of error is also much lower in this set of sequences as compared to the kanamycin-positive set, likely due to overall cleaner sequencing run. These data show slightly more conversion errors when dBTP was used in the conversion PCR (47 errors) compared with when dBTP was absent in the conversion PCR (30).

Table S6: Comparison of sequences between selection/no selection data sets

	KanR Positive	KanR All
Non-Conversion Error Rate	2.0%	0.8%
S Conversion Total Error Rate	4.6%	3.5%
S Conversion S->C Errors	0.9%	1.1%
S Conversion S->Other Errors	3.7%	2.4%
B Conversion Total Error	5.4%	2.2%
B Conversion B->G Errors	1.8%	0.4%
B Conversion B->Other Errors	3.6%	1.8%

Table S7: Fragment sequences in the 32A construct

Order	Oligonucleotide	Strand
1	GCBTTGCGSCCATCBAGCAGTGGCTGTATACCGGABGTGGGSCGGCTCST	Minus
2	SGATGGBCGCAASGCTGTTTACTCGGTACAGTAGAGGGCGBACGABTGTBG	Plus
3	STGTBCCTGSCCGCTTCAAAACCCTTCATTCTACACASTCGTSCGCC	Minus
4	GCGGBCAGGSGACABAGAATACTCTATAGGATCACBCGCTBTCAGGGTST	Plus
5	CABCCCGTSCGTABGTATCGATTTCTTGGCATABACCCTGASAGCGSGT	Minus
6	CSTACGBACGGGSGTGAAGTGTGAAAACAACCGTSAGGTGCSGGGTS GG	Plus
7	CCBCGGCBTCCTABGTGTATACCAATAGGTCCAGTCCBACCCBGCACCTB	Minus
8	CSTAGGASGCCGSGGATAAGAGATGTTCCCTAGACSTCAGACBGGACBCT	Plus
9	GSGBGGBCGCGTBTGTTACTCACAATAATGAGSGTCCSGTCTGABGT	Minus
10	SACGCGSGCCSACBCAACTACGTAGTGACATGCTABTCTCCSGCTCGCCB	Plus
11	CGSGCSCGGBATBCCTTTACATCAGTTCGCGATCTSGGCGAGCBGGAGAS	Minus
12	GGSATSCCBGCBGCTTTAGTCTTCTAACACAGASGTCGCTASCTCBCGT	Plus
13	BCGTGCTCSAGCSCCAGAGGAGAGAGAAAAGTTTACGSGAGBTAGCGACBT	Minus
14	GGBGCTBGACGACGSATACAATACCCACTATGGTCSGGGAASGGGGSCCC	Plus
15	CGBATGTBCGCTCBCATTGATGATATGCCTCAACAGGGBCCCCBTCCCB	Minus
16	GSGAGCGSACATSCGACTTTTCATGTATCTATAACGSTACGBCGTCCSAT	Plus
17	BCCTCATCBCSGCGGCTAAGATCGTGAGCTAATATBGGACGSCGTABCGT	Minus
18	CCGCBGSGATGAGGSAATAGTCGTGTTGTAGAGAACCBCTCABGGACBCG	Plus
19	CGCSABGCCCBGGTBTCAAGAAGAAGTCTTATGGGCGSGTCCSTGAGSGG	Minus
20	SACCSGGGCTBGCCTAGAAATGTTTTGCTTAAABASGCCTAGBGGGCBT	Plus
21	STCGGCABGGGAAGSCCAGTTTTGTAGCTAACTASGCCCSTAGGCBTST	Minus
22	BCTTCCCSTGCCGABATTAGCGACTTAAGGATAACCGCGSABTGGASGGC	Plus
23	BGCCBAAGAGCCBCBAGTCGGTGCATTTGTCTTAGGCCBTCCASTBCGCG	Minus
24	SGSGGCTCTTSGGCSATTCATCTATAGAACTTGACBGGBGCGSGTASGGT	Plus
25	GGACGBCAASGGGCGAGCCGTATCTTCTGTATTACCBTACBCGSCCSGT	Minus
26	GCCCBTTGSCGTBCCAGTATCCATTCCATACGTTGGBAACCABTCCGGSG	Plus
27	SCCGGBCGGBTTCCBTATACCTTTTCATATGATGCCBCCGGASTGGTTSC	Minus
28	SGGAASCCGSCCGGBTATAGGTTTAGATGTTAGASTCGGTCSGCSAGSGT	Plus
29	SGGACTCCBCGASCCTAGTACAATGTTACATTGACBCTBGCBGACCGABT	Minus
30	GGBTCGSGGAGTCCBAAATGGAATAGTAGAGCATCCGCGBGSTCATTCS	Plus
31	CSGTGGGGBGCACBTTATGATGGTGAAATGTTTAGBGAATGABCSCGCG	Minus
32	SGTGCSACCCACBGTGAAAAGTAGACGATCTAABTGTTGCBAGCGCSCT	Plus

Table S8: Fragment Sequences in the 32B construct

Order	Oligonucleotide	Strand
1	CTGTCGGATCCCGCTTGGATGTGTACGCTTGGGGTAGCTGGGAGGCTCTT	Minus
2	AGCGGGATCCGACAGGGTTGACGATTACAAAGGCAGGAGGGCATCAACTG	Plus
3	CCGGTGAGCTCCTCAGGATGGGTTAAGAAACAAAACAGTTGATGCCCTCC	Minus
4	TGAGGAGCTCACCGGATCAATACATGACGAAGTAGCCGATTTGGAGTGTT	Plus
5	CTATCGCCTCGGCATATGATTCTACATTTGACAAAAACACTCCAAATCGGCT	Minus
6	ATGCCGAGGCGATAGCATTCTTTTTAAACACCTTTAGCCGAAGTATGGCC	Plus
7	GTGCAAGGCCTGATTACCATTGATACTTCACTTCTGGCCATAGTTCGGCT	Minus
8	AATCAGGCCTTGCACTTGCTACATTACTTTCTAGACAAAGAGACGGGT	Plus
9	GCAATGACGGAAGTGAACCATAACTAGCTCGAGTAACCCGTCTCTTTGTCT	Minus
10	CAAGTCCGTCATTGCTTGAAGGACCGAATTCATTAGCCGATAGGTACGTC	Plus
11	ACGAACGAGCCGTTATTCTATAGAGCTCGTGAGACGACGTACCTATCGGC	Minus
12	TAACGGCTCGTTCGTATAACAATACACTTTCACACGTTCTTCAGTGACGT	Plus
13	CGCAAAGAGCGACAGAAGCAACGTGGATAAGCTCTACGTCACTGAAGAACGT	Minus
14	CTGTCGCTCTTTGCGAAAGTAAGTTAACATGTTTGGACCACTGCCAGTAC	Plus
15	CGCTCTTCCTGGCTAGTCATCTGTGGGTATTCCTCGTACTGGCAGTGGTC	Minus
16	TAGCCAGGAAGAGCGATTACGGAAAGGTCAAAAATCTTCCAGGGCACGT	Plus
17	GGGTCATCCCTACGGTGTTATCTTTCCGCTGATAACGTGCCCTGGAAAGAT	Minus
18	CCGTAGGGATGACCCTCTAGAAGTCGAGGGGTAGTAGCTAGGCCACAGAC	Plus
19	ACCAGGACGTCTGGATCTAAGTATGTCTCTAAGCAGTCTGTGGCCTAGCT	Minus
20	TCCAGACGTCCTGGTCTTAGAGAACATATGTAAACGACGTGTACCGTTCT	Plus
21	CAGCGTGAGGCCAATTTAGTTACTCATTCCCCAGTAGAACGGTACACGTCGT	Minus
22	ATTGGCCTCACGCTGATTGGTCTTATCAGACGCTGGGCGTTTAAACCGGT	Plus
23	ACGCCACTTACGCCAGCGATAAAGGCCTACTCAACACCGGTTTAAACGCC	Minus
24	TGGCGTAAGTGGCGTGCTGAAGTCCTATAGTTTAGGAAGCAACAGCATGT	Plus
25	CGTCAGTTAACCAGCAACATTGAGTATTCGCCTGAAACATGCTGTTGCTTCCT	Minus
26	TGCGGTTAACTGACGACAAGCATTACATTCACCATAAATGCCACAGGACG	Plus
27	GCTTCCTTCTCAGCCTCCGACTCTAGTTCATAGTACGTCCTGTGGCATT	Minus
28	GGCTGAGAAGGAAGCGGTATACTCTGTTTTCTTATAGTTCCGACCGACGT	Plus
29	GAGCGGAAGTGTGCTTAGTAATGACGTCAACCTATACGTCGGTCGGAACTAT	Minus
30	AGCACACTTCGCTCTCTTTCTGAGTATGGTCCTTAAGACTGGGCACAAC	Plus
31	CTCTTGATCCACCGCACCTGTGTACTACTTCTCTGTTGTGCCAGTCTT	Minus
32	CGGTGGATCCAAGAGATTAACTGGCTTTACCAAGGATAGTACGCGAGT	Plus

Table S9: Fragment sequences in the 32C construct

Order	Oligonucleotide	Strand
1	TGCTTGGATCCCCTCCCTCTATGAAGAGACCTCGTATGGCGTTGCACTGT	Minus
2	GAGGGGATCCAAGCAATCCGCAGTAAGCTGTCAAATATCCCCACCACCAC	Plus
3	CTGAGGACGTCGCATTAGCTGAAGCCTTACGGATAGTGGTGGTGGGGATA	Minus
4	ATGCGACGTCCTCAGATTGTGCGCTCTTCCGCAAGCCCACTAAAGACCT	Plus
5	CCCTAGTTCGGGACACCGTATCTAACTTTCTAACAGGTCTTTAGTGGGCTT	Minus
6	TGTCCCGAACTAGGGGGAGTTAGAGCTCTGATAACCAGTGGCCTGTTTTG	Plus
7	GCTCGTTTAAACCGCTAGTGTAGCATGGTCAATTCCAAAACAGGCCACTG	Minus
8	GCGGTTTAAACGAGCAGAATTGACTTCTAAACGATGGAGCACAGGGTCAT	Plus
9	GACACATGGGCTTGTCTAATCACTCACTTCTTATGACCCTGTGCTCCAT	Minus
10	ACAAGCCCATGTGTCTAGCTATAGGTGTAAGTGCGCAACGTATGGTACG	Plus
11	TTGCGTCCACGTTTGTAGACCAGACGTCCGTAATTCGTACCATACGTTGC	Minus
12	CAAACGTGGACGCAAAAATCTCTAGGGCTAACCATACACGTGAACCCGT	Plus
13	GTCACCCGTGCTGTAAAGCAAATCTTGGGGATATACGGGTTCACGTGTAAT	Minus
14	TACAGCACGGGTGACACTTAACAGGCCTAACTCTGCAGGAACCTTGCTC	Plus
15	GGGCTACGAAGTCGATAGAAGGACTACACCTGCCAGAGCAAAGTTCCTGC	Minus
16	TCGACTTCGTAGCCCAAAGCACATATCCAATAGAAACCATTTGCGAAGGT	Plus
17	TGGCCTCGTGCATATATGAGTATCATTGATCTTTGACCTTCGCAAATGGTTT	Minus
18	ATACGCACGAGGCCAACCATAACCTAAACGGCTATGGCAAACGCGACTCA	Plus
19	GCGAGGTTAACGCTTTGCCGAGTCACTAGCAATACTGAGTCGCGTTTGCC	Minus
20	AAGCGTTAACCTCGCGAAGAGATAAGCAGATATACACGGTATAGTGCCTT	Plus
21	CACTTCAGGCTGTCGCTTCGAATGACAGGATAGTAAAGGCACTATACCGTGT	Minus
22	CGACAGCCTGAAGTGAGATATGGGTGAATTGATTAAGGGGAGCTCGACGT	Plus
23	GTTTGGACGAATGGGATATCACTTTAAACCGACACACGTCGAGCTCCCT	Minus
24	CCCATTCGTCCAAACGCAGGATTTCTTTGTGTATTCCGTGGGACCACAT	Plus
25	CCTGAAGGCCTACCTGGTTGAAACCCTAACTGCTGATGTGGTCCCACGGAAT	Minus
26	AGGTAGGCCTTCAGGAGGGATATGTTACACATTGGGACACGCGATAAGC	Plus
27	GGGCTCCGTTTTCTTGCAAACTGGATCACCAGATGCTTATCGCGTGTCC	Minus
28	AAGAAAACGGAGCCCTTAGATGATGATGGAATTAAGAACCGCACATGAGT	Plus
29	CACGGTCAGTGTCTGATACTACGTTAACGACAATTACTCATGTGCGGTTCTT	Minus
30	CAGACACTGACCGTGACCATAAGATTAGATTACTATCCACCCTGCCAAA	Plus
31	GCCACGGATCCTAGAAGAAATCCTATTGGCTGGAATTTGGGCAGGGTGGA	Minus
32	TCTAGGATCCGTGGCTAACAGGAATGATGTTTAACTTCACTCACCTCGAT	Plus

Table S10: Primer sequences to analyze the 32A construct

Order	Primer	Orientation
1	ABGAGCCSCCCBGCU	+
2	ABCACTCCBAASC GGCU	-
3	AGCCGBTTSGGAGTGSU	+
4	ABCCCGTCSTTTGSCU	-
5	AGBCAAAGBGACGGGSU	+
6	ACGSCACSGAAGABCGU	-
7	ACGSTCTTCBGTGBCGU	+
8	ACGSGCCCSGGAAGBU	-
9	ASCTTTCCBGGGCBBCGU	+
10	AGBACGGTBCACGSCGU	-
11	ACGBCGTGSACCGTSCU	+
12	ACBTGCTGSTGCTSCCU	-
13	AGGBAGCABCAGCASGU	+
14	ACGSCGGSCGGAACBU	-
15	ASAGTTCCGBCCGBCGU	+
16	ACSCGCGTACSATCCSU	-

Table S11: Primer sequences to analyze the 32B constructs and sub-constructs

Order	Primer	Orientation
1	AAGAGCCTCCAGCT	+
2	AACACTCCAAATCGGCT	-
3	AGCCGATTTGGAGTGTT	+
4	AACCCGTCTCTTTGTCT	-
5	AGACAAAGAGACGGGTT	+
6	ACGTCACTGAAGAACGT	-
7	ACGTTCTTCAGTGACGT	+
8	ACGTGCCCTGGAAAGAT	-
9	ATCTTTCCAGGGCACGT	+
10	AGAACGGTACACGTCGT	-
11	ACGACGTGTACCGTTCT	+
12	ACATGCTGTTGCTTCCT	-
13	AGGAAGCAACAGCATGT	+
14	ACGTGCGTCGGAACAT	-
15	ATAGTTCCGACCGACGT	+
16	ACTCGCGTACTATCCTT	-

Table S12: Primer sequences to analyze the 32C construct

Order	Primer	Orientation
1	ACAGTGCAACGCCAT	+
2	AGGTCTTTAGTGGGCTT	-
3	AAGCCCACTAAAGACCT	+
4	ATGACCCTGTGCTCCAT	-
5	ATGGAGCACAGGGTCAT	+
6	ACGGGTTCACGTGTAAT	-
7	ATTACACGTGAACCCGT	+
8	ACCTTCGCAAATGGTTT	-
9	AAACCATTTGCGAAGGT	+
10	AAGGCACTATACCGTGT	-
11	ACACGGTATAGTGCCTT	+
12	ATGTGGTCCCACGGAAT	-
13	ATTCCGTGGGACCACAT	+
14	ACTCATGTGCGTTCTT	-
15	AAGAACCGCACATGAGT	+
16	ATCGAGGTGAGTGAAGT	-

Forward Fragments: S GATGGBCGCAAS GCTGTTTACTCGGTCACTAGAGGGCGBACGAB
Reverse Fragments: T S CTCGGC S GGGTGBAGGCCATATGTCGGTGACGABCTACCSGCCGTTBCG CCGCSTGCT S
Assembled Construct: 1 ABGAGCCGBCCCACSTCCGGTATACAGCCACTGCTSGATGGBCGCAASGCTGTTTACTCGGTCACTAGAGGGCGBACGAB 80

Forward Fragments: TGTBG GCGGBBAGGS GACABAGAATACTCTATAGGATCABCBCGTBTCAAGGTS T
Reverse Fragments: ACASCATCCTTACTTCCAAAACTTCGCCSGTCCBCTGT S TSGCGASAGTCCCBATACGG
Assembled Construct: 81 TGTBGTAGGAATGAAGGGTTTTGAAGCGGBBAGGS GACABAGAATACTCTATAGGATCABCBCGTBTCAAGGTSATATGCC 160

Forward Fragments: CSTACGBACGGSGTGAGAACTGTGAAAACAACCGTSAGGTGCSGGGTS GG
Reverse Fragments: TTCCTTTAGCTATGBATGCS TGCCCBAC BTCCACGBCCCBCTGACCTGGATAACCAT A
Assembled Construct: 161 AAGGAAATCGATACSTACGBACGGSGTGAGAACTGTGAAAACAACCGTSAGGTGCSGGGTSGGACTGGACCTATTGGTAT 240

Forward Fragments: CSTAGGASGCCSGGATAAGAGATGTTCCCTAGACSTCAGACBGGACBCT S ACGCGSGC
Reverse Fragments: TGTGBATCCTBCGGCBCC TGBAGTCTGSCCTGSGAGTAATCAACACTCATTGTBTGCGCB CG
Assembled Construct: 241 ACACSTAGGASGCCSGGATAAGAGATGTTCCCTAGACSTCAGACBGGACBCTCATTAGTTGTGAGTAACASACGCGSGC 320

Forward Fragments: CSACBCAACTACGTAGTGACATGCTABTCTCCSGCTCGCCB GGSATSCCBGBCBCGTTTA
Reverse Fragments: GBTGSG S AGAGGBCGAGCGGSTCTACGCGTTGACTACATTTCCBTABGGCSGSGC
Assembled Construct: 321 CSACBCAACTACGTAGTGACATGCTABTCTCCSGCTCGCCBAGATCGGAACTGATGTAAAGSATSCCBGBCBCGTTTA 400

Forward Fragments: GTCTTCTAACACAGASGTCGCTASCTCBCT GGBGCTBGACGACGSATACAATACCCACTAT
Reverse Fragments: TBCAGCGATBGAGSGCATTTGAAAGAGAGAGGAGACCS CGASCTGTGCB
Assembled Construct: 401 GTCTTCTAACACAGASGTCGCTASCTCBCTAACTTTCTCTCTCTCTGGBGCTBGACGACGSATACAATACCCACTAT 480

Forward Fragments: GGTCSGGGAASGGGSGCC GSAGCGSACATSCGACTTTTCATGTATCTATAACGSTACG
Reverse Fragments: BCCCTTBCCCCBGGGACAACTCCGTATAGTAGTTACBCTCGCBTGTABGC TGCBATGC
Assembled Construct: 481 GGTCSGGGAASGGGSGCCGTGTGAGGCATATCATCAATGSGAGCGSACATSCGACTTTTCATGTATCTATAACGSTACG 560

Forward Fragments: BCGTCCSAT CCGCBGSGATGAGGS AATAGTCGTGTTGTAGAGAACCBCTCABGGACBCG
Reverse Fragments: SGCAGGBTATAATCGAGTGCTAGAATCGGCGSCBCTACTCCB GSGAGTSCCTGSGCGGG
Assembled Construct: 561 BCGTCCSATATTAGCTCACGATCTTAGCCGCBGSGATGAGGS AATAGTCGTGTTGTAGAGAACCBCTCABGGACBCGCC 640

Forward Fragments: S ACCSGGGCSTBGCCTAGAAATGTTTTGCTTAAABASGCCTAGBGGGCBT
Reverse Fragments: TATTTCTGAAGAAGAACTBTGGBCCCGBASCGC TSTBCGGATCSCCGSATCAATCGATGTTT
Assembled Construct: 641 ATAAGACTTCTTTCTTGASACCSGGGCTSBGCGTAGAAATGTTTTGCTTAAABASGCCTAGBGGCBTAGTTAGCTACAAA 720

Forward Fragments: BCTTCCSTGCCGABATTAGCGACTTAAGGATAACCGCSABTGGASGGC S GS GG
Reverse Fragments: TGACCSGAAGGGBACGGCT S GCGCBT S ACCTBCCGGATTCTGTTTACGTGGCTGABCBCC
Assembled Construct: 721 ACTGGBCTTCCCTSGCCGABATTAGCGACTTAAGGATAACCGCSABTGGASGGCCTAAGACAAATGCACCGACTSGSGG 800

Forward Fragments: CTCTTSGGCSATTCATCTATAGAACTTGACBGGBGGCSGTASGGT GCCCBTTGSCGTBCCAG
Reverse Fragments: GAGAA BCCGB TGS CCGCB CATBCCATTATGCTTCTATGCCGACGGGSAACBGCASGG
Assembled Construct: 801 CTCTTSGGCSATTCATCTATAGAACTTGACBGGBGGCSGTASGGTAATACAGAAGATACGGCTGCCBTTGSCGTBCCAG 880

Forward Fragments: TATCCATTCCATACGTTGGBAACCABTCCGGSG S GGAASCCGSCCGGBTATAGGTTTAGA
Reverse Fragments: CTTGGTSAGGCCBCCGTAGTATACTTTCCCATATBCCTTBGGCBGGCCS
Assembled Construct: 881 TATCCATTCCATACGTTGGBAACCABTCCGGSGGCATCATATGAAAGGGTATASGGAASCCGSCCGGBTATAGGTTTAGA 960

Forward Fragments: TGTTAGASTCGGTCSGCSAGSGT GGBTCGSGGAGTCCBAAATGGAATAGTAGAGCATCCGCG
Reverse Fragments: TBAGCCAGBCGBTBCAGTTACATTGTAACATGATCCSAGCBCTCAGGS GCGC
Assembled Construct: 961 TGTTAGASTCGGTCSGCSAGSGTCAATGTAACATTGTACTAGGBTCGSGGAGTCCBAAATGGAATAGTAGAGCATCCGCG 1040

Forward Fragments: BGSTCATTCS C SGTGCSACCCACBGTGAAAAGTAGACGATCTAABTGTTGCBAGCGCS C
Reverse Fragments: SCBAGTAAGBGATTTGTAAAGTGGTAGTATTBCACGBTGGGGTGS C
Assembled Construct: 1041 BGSTCATTCSCTAAACATTTACCATCATAASGTGCSACCCACBGTGAAAAGTAGACGATCTAABTGTTGCBAGCGCS C 1120

Forward Fragments: T
Reverse Fragments:
Assembled Construct: 1121 T 1121

Figure S1: The 32A assembly. Shown (top two lines) are the forward and reverse oligonucleotide fragments (16 of each, respectively) together with their intended autonomous hybridization to give the target 1135 bp assembly (bottom line). The assembly was designed to be completed by filling in the gaps with Phusion DNA polymerase and sealing the nicks with *Taq* DNA ligase to give, before conversion, the AEGIS construct shown in the third line. Subsequently, **S** and **B** were converted to T and A, respectively, by conversion PCR.

Forward Fragments: AGCGGGATCCGACAGGGTTGACGATTACAAAGGCAGGAGGGCATC
Reverse Fragments: TTCTCGGAGGGTCGATGGGGTTCGCATGTGTAGGTTCCGCCCTAGGCTGTCTCCCGTAG
Assembled Construct: 1 AAGAGCCTCCAGCTACCCCAAGCGTACACATCCAAGCGGGATCCGACAGGGTTGACGATTACAAAGGCAGGAGGGCATC 80

Forward Fragments: AACTG TGAGGAGCTCACC GGATCAATACATGACGAAGTAGCCGATTGGAGTGT
Reverse Fragments: TTGACAAACAAAGAATTGGGTAGGACTCCTCGAGTGGCC TCGGCTAAACCTCACAAAAACA
Assembled Construct: 81 AACTGTTTTGTTTCTTAACCCATCCTGAGGAGCTCACC GGATCAATACATGACGAAGTAGCCGATTGGAGTGT TTTTGT 160

Forward Fragments: ATGCCGAGGCGATAGCATTCTTTTTAAACACCTTTAGCCGAACATGGCC
Reverse Fragments: GTTTACATCTTAGTATACGGCTCCGCTATC TCGGCTTGATACCGGTCTTCACTTCATAGT
Assembled Construct: 161 CAAATGTAGAATCATATGCCGAGGCGATAGCATTCTTTTTAAACACCTTTAGCCGAACATGGCCAGAAGTGAAGTATCA 240

Forward Fragments: AATCAGGCCTTGCACTTGCTACATTACTTTCTAGACAAAGAGACGGGTT CAAGT
Reverse Fragments: TACCATTAGTCCGGAACGTG TCTGTTTCTCTGCCCAATGAGCTCGATCAATACCAAAGTTCA
Assembled Construct: 241 ATGGTAATCAGGCCTTGCACTTGCTACATTACTTTCTAGACAAAGAGACGGGTTACTCGAGCTAGTTATGGTTTCAAGT 320

Forward Fragments: CCGTCATTGCTTGAAGGACCGAATTCAATAGCCGATAGGTACGTC TAACGGCTCGTTCTGT
Reverse Fragments: GGCAGTAACG CGGCTATCCATGCAGCAGAGTGCTCGAGATATCTTATTGCCGAGCAAGCA
Assembled Construct: 321 CCGTCATTGCTTGAAGGACCGAATTCAATAGCCGATAGGTACGTCGTTCTACGAGCTCTATAGAATAACGGCTCGTTCTGT 400

Forward Fragments: ATAACAATACACTTTACACGTTCTTCAGTGACGT CTGTGCTCTTTGCGAAAGTAAGTT
Reverse Fragments: TCAAGAAGTCACTGCATCTCGAATAGGTGCAACGAAGACAGCGAGAAACGC
Assembled Construct: 401 ATAACAATACACTTTACACGTTCTTCAGTGACGTAGAGCTTATCCACGTTGCTTCTGTGCTCTTTGCGAAAGTAAGTT 480

Forward Fragments: AACATGTTTGGACCACTGCCAGTAC TAGCCAGGAAGAGCGATTACGGAAAGGTCAAAAAT
Reverse Fragments: TGGTGACGGTCATGCTCTTATGGGTGCTACTGATCGGTCTTCTCGC TA
Assembled Construct: 481 AACATGTTTGGACCACTGCCAGTACGAGGAATACCCACAGATGACTAGCCAGGAAGAGCGATTACGGAAAGGTCAAAAAT 560

Forward Fragments: CTTTCCAGGGCACGT CCGTAGGGATGACCCCTAGAAAGTCGAGGGGTAGTAGCTAGGCCA
Reverse Fragments: GAAAGGTCCCGTGCAATAGTCGCCTTTCTATTGTGGCATCCCTACTGGG TCGATCCGGT
Assembled Construct: 561 CTTTCCAGGGCACGTATCAGCGGAAAAGATAACACCGTAGGGATGACCCCTAGAAAGTCGAGGGGTAGTAGCTAGGCCA 640

Forward Fragments: CAGAC TCCAGACGTCCTGGTCTTAGAGAACATATGTAACGACGTGTACCGTTCT
Reverse Fragments: GTCTGACGAATCTCTGTATGAATCTAGGTCTGCAGGACCA TGCTGCACATGGCAAGATGACC
Assembled Construct: 641 CAGACTGCTTAGAGACATACTTAGATCCAGACGTCCTGGTCTTAGAGAACATATGTAACGACGTGTACCGTTCTACTGG 720

Forward Fragments: ATTGGCCTCACGCTGATTGGTCTTATCAGACGCTGGGCGTTTAAACCGT
Reverse Fragments: CCTTACTCATTGATTTAACCGGAGTGCAC CCGCAATTTGGCCACAACATCATCCGGAAA
Assembled Construct: 721 GGAATGAGTAACATAATTGGCCTCACGCTGATTGGTCTTATCAGACGCTGGGCGTTTAAACCGGTGTTGAGTAGGCCCTTT 800

Forward Fragments: TGGCGTAAGTGCGTGTCTGAAGTCCTATAGTTTAGGAAGCAACAGCATGT TCGCG
Reverse Fragments: TAGCGACCGCATTACCGCA TCCTTCGTTGTCGTACAAAGTCCGCTTATGAGTTACAACGCC
Assembled Construct: 801 ATCGTGGCGTAAGTGCGTGTCTGAAGTCCTATAGTTTAGGAAGCAACAGCATGTTTCAGGCGAATACTCAATGTTGCGG 880

Forward Fragments: TTAAGTGACGACAAGCATTACATTACCATAAATGCCACAGGACG GGCTGAGAAGGAAGC
Reverse Fragments: AATTGACTGC TTTACGGTGCTGCTGATGATACTTGATCTCAGCCTCCGACTCTTCTTTCG
Assembled Construct: 881 TTAAGTGACGACAAGCATTACATTACCATAAATGCCACAGGACGTAATGAACTAGAGTCGGAGGCTGAGAAGGAAGC 960

Forward Fragments: GGTATACTCTGTTTTCTTATAGTTCCGACCGACGT AGCACATTCCGCTCTCTTTCTGAG
Reverse Fragments: TATCAAGGCTGGCTGCATATCCAAGTGCAGTAATGATTGCTGTGAAGGCGAG
Assembled Construct: 961 GGTATACTCTGTTTTCTTATAGTTCCGACCGACGTATAGGTTGACGTCATTACTAAGCACACTTCCGCTCTCTTTCTGAG 1040

Forward Fragments: TATGGTCCTTAAGACTGGGCACAAC CGGTGGATCCAAGAGATTACACTGGCTTTACCCAA
Reverse Fragments: TTCTGACCCGTGTTGTCTTCTCATCATGTGTCCACGCCACCTAGGTTCTC
Assembled Construct: 1041 TATGGTCCTTAAGACTGGGCACAACAGAGAAGTAGTACACAGGTGCGGTGGATCCAAGAGATTACACTGGCTTTACCCAA 1120

Forward Fragments: GGATAGTACGCGAGT
Reverse Fragments:
Assembled Construct: 1056 GGATAGTACGCGAGT 1135

Figure S2: The 32B assembly. Shown (top two lines) are the forward and reverse synthetic fragments (16 of each) together with their intended overlap hybridization to give the target bp assembly (bottom line). The assembly was designed to be completed by filling in the gaps with Phusion DNA polymerase and sealing the nicks with T4 DNA ligase.

Forward Fragments: GAGGGGATCCAAGCAATCCGCAGTAAGCTGTCAAATATCCCCACC
Reverse Fragments: TGTACAGTTGCGGTATGCTCCAGAGAAGTATCTCCCTCCCCTAGGTTCTG ATAGGGGTGG
Assembled Construct: 1 ACAGTGCAACGCCATACGAGGTCTCTTCATAGAGGGAGGGGATCCAAGCAATCCGCAGTAAGCTGTCAAATATCCCCACC 80

Forward Fragments: ACCAC ATGCGACGTCTCAGATTGTGCGCTCTTTCGCAAGCCCACTAAAGACCT
Reverse Fragments: TGGTGATAGGCATTCCGAAGTCGATTACGCTGCAGGAATC TTCGGGTGATTTCTGGACAATC
Assembled Construct: 81 ACCACTATCCGTAAGGCTTCAGCTAATGCGACGTCTCAGATTGTGCGCTCTTTCGCAAGCCCACTAAAGACCTGTTAG 160

Forward Fragments: TGTCCGAAC TAGGGGGAGTTAGAGCTCTGATAACCACTGGCCTGTTTTG
Reverse Fragments: TTTCAAATCTATGCCACAGGGCTTGATCCG GTCACCGGACAAAACCTTAACTGGTACGAT
Assembled Construct: 161 AAAGTTTAGATACGGTGTCCCGAACTAGGGGGAGTTAGAGCTCTGATAACCACTGGCCTGTTTTGGAATTGACCATGCTA 240

Forward Fragments: GCGGTTTTAAACGAGCAGAATTGACTTCTAAACGATGGAGCACAGGGTCAT ACAAG
Reverse Fragments: GTGATCGCCAAATTTGCTCG TACCTCGTGCTCCAGTATTCCTACTCACTACAATACGCTT
Assembled Construct: 241 CACTAGCGGTTTTAAACGAGCAGAATTGACTTCTAAACGATGGAGCACAGGGTCATAAGAATGAGTTGATGTTATGACAAG 320

Forward Fragments: CCCATGTGTCGTAGCTATAGGTGTAAGTGCGCAACGTATGGTACG CAAACGTGGACGCAA
Reverse Fragments: GGGTACACAG CGTTGCATACCATGCTTCATGCCTGCAGACCAGATGTTTGCACCTGCGTT
Assembled Construct: 321 CCCATGTGTCGTAGCTATAGGTGTAAGTGCGCAACGTATGGTACGAAGTACGGACGTCTGGTCTACAAACGTGGACGCAA 400

Forward Fragments: AAATCTCTAGGGCTAACCATTAACAGTGAACCCGT TACAGCACGGGTGACACTTAACAGG
Reverse Fragments: TAATGTGCATTTGGGCATATAGGGGTTTTCTAAACGAAATGTGCTGCCCACTG
Assembled Construct: 401 AAATCTCTAGGGCTAACCATTAACAGTGAACCCGTATATCCCCAAAGATTTGCTTTACAGCACGGGTGACACTTAACAGG 480

Forward Fragments: CCTAAACTCTGCAGGAAC TTTGCTC TCGACTTCGTAGCCCCAAAGCACATATCCAATAGAA
Reverse Fragments: CGTCCTTGAAACGAGACCGTCCACATCAGGAAGATAGCTGAAGCATCGGG TT
Assembled Construct: 481 CCTAAACTCTGCAGGAAC TTTGCTCTGGCAGGTGTAGTCTTCTATCGACTTCGTAGCCCCAAAGCACATATCCAATAGAA 560

Forward Fragments: ACCATTTGCGAAGGT ATACGCACGAGGCCAACCATAACTAAACGGCTATGGCAAACGCG
Reverse Fragments: TGGTAAACGCTTCCAGTTTTCTAGTTACTATGAGTATATGCGTGCTCCGGT CCGTTTGCGC
Assembled Construct: 561 ACCATTTGCGAAGGTCAAAGATCAATGATACTCATATACGCACGAGGCCAACCATAACTAAACGGCTATGGCAAACGCG 640

Forward Fragments: ACTCA AAGCGTTAACCTCGCGAAGAGATAAGCAGATATACACGGTATAGTGCCTT
Reverse Fragments: TGAGTCATAACGATCACTGAGCCGTTTCGCAATTGGAGCG TGTGCCATATACGGAATGAT
Assembled Construct: 641 ACTCAGTATTGCTAGTGACTCGGC AAAGCGTTAACCTCGCGAAGAGATAAGCAGATATACACGGTATAGTGCCTTTACTA 720

Forward Fragments: CGACAGCCTGAAGTGAGATATGGGTGAATTGATTAAGGGGAGCTCGACGT
Reverse Fragments: AGGACAGTAAGCTTCGCTGTCTGGACTTCAC TCCCTCGAGCTGCACACAGCCAAATTTCA
Assembled Construct: 721 TCTGTCTATTGGAAGCGACAGCCTGAAGTGAGATATGGGTGAATTGATTAAGGGGAGCTCGACGTGTGTCTCGGTTTAAAGT 800

Forward Fragments: CCCATTCTGTC AAACGACAGGATTTCTTTGTGATTCCGTGGGACCACAT AGGTA
Reverse Fragments: CTATAGGGTAAGCAGGTTTTG TAAGGCACCCTGGTGTAGTCGTCATCCCAAAGTTGGTCCAT
Assembled Construct: 801 GATATCCCATTCGTCCAAACGACAGGATTTCTTTGTGATTCCGTGGGACCACATCAGCAGTTAGGGTTTCAACCAGGTA 880

Forward Fragments: GGCCTTCAGGAGGGATATGTTACACATTGGGACACGCGATAAGC AAGAAAAAGGAGCCC
Reverse Fragments: CCGGAAGTCC CCTGTGCGCTATTCTGAGACCACTAGGTCAAAACGTTCTTTTGCCTCGGG
Assembled Construct: 881 GGCCTTCAGGAGGGATATGTTACACATTGGGACACGCGATAAGCATCTGGTGATCCAGTTTTGCAAGAAAAAGGAGCCC 960

Forward Fragments: TTAGATGATGATGGAATTAAGAACCACATGAGT CAGACACTGACCGTGACCATAAGAT
Reverse Fragments: TTCTTGGCGTGTA CTCTTAACAGCAATTGCATCATAGTCTGTGACTGGCAC
Assembled Construct: 961 TTAGATGATGATGGAATTAAGAACCACATGAGTAATTGTCTGTTAACGTAGTATCAGACACTGACCGTGACCATAAGAT 1040

Forward Fragments: TAGATTACTATCCACCCTGCCAAA TCTAGGATCCGTGGCTAACAGGAATGATGTTTAACT
Reverse Fragments: AGGTGGGACGGGTTTAAGGTCGGTTATCCTAAAGAAGATCCTAGGCACCG
Assembled Construct: 1041 TAGATTACTATCCACCCTGCCCAAATTCAGCCAAATAGGATTTCTTCTAGGATCCGTGGCTAACAGGAATGATGTTTAACT 1120

Forward Fragments: TTCACCTCACCTCGAT
Reverse Fragments:
Assembled Construct: 1056 TTCACCTCACCTCGAT 1135

Figure S3: The 32C assembly. Shown (top two lines) are the forward and reverse oligonucleotide fragments (16 of each, respectively) together with their intended autonomous hybridization to give the target 1135 bp assembly (bottom line). The assembly was designed to be completed by filling in the gaps with Phusion DNA polymerase and sealing the nicks with T4 DNA ligase.




Figure S4: Two independent 16-fragments of the 32B construct were ligated by T4 DNA Ligase, and full-length assemblies were recovered by PCR. Shown is an agarose gel resolving the products, obtained after the second ligation, followed by PCR. Ladder is at left.




Figure S5: 32C assembly resolved on a 1.2% TAE agarose gel stained with ethidium bromide. Sample lanes from left to right represent 5 PCR amplifications (2 μ l of each reaction): a non-template control PCR and two sets of duplicate AEL reactions with per-oligo concentrations of 63 and 125 nM, respectively. Ladder is at left. A band whose length (1135 bp) is consistent with the PCR product of the 32 oligonucleotide AEL construct is present in one, but not both replicates, of the two 32O AEL reactions at a per-oligo concentration of 125 nM. This amount is double that of 63 nM, the per-oligo concentration used in the AEL construction of the Kanamycin resistance gene as well as in two of the AEL reactions represented on the gel. The thermal profile was as follows: a pre-incubation (no enzyme) of 5 min at 80°C. 30 min at 40°C and 59 min at 50°C.




Figure S6: Predicted higher-order DNA structure of the Oligo #17 from the 32B assembly, obtained via Oligo Analyzer 3.1 (Integrated DNA Technologies). The four most possible hairpin structures are shown. Similar “folds” can be proposed, of course, for essentially any set of oligonucleotides built from only standard nucleotides.

References

1. Gibson, D. G., *Meth. Enzymol.* **2011**, 498, 349-361.
2. Bradley, K. M., Benner, S. A. *Beilstein J. Org. Chem.* accompanying paper
3. Caruthers, M. H., Kleppe, K., van de Sande, J. H., Sgaramella, V., Agarwal, K.L., Büchi, H., Gupta, N.K., Kumar, A., Ohtsuka, E., RajBhandary, U.L., Terao, T., Weber, H., Yamada, T., Khorana, H.G. *J. Mol. Biol.* **1972**, 72, 475-492.
4. Edge, M. D., Greene, A. R., Heathcliffe, G. R., Meacock, P. A., Schuch, W., Scanlon, D. B., Atkinson, T. C., Newton, C. R., Markham, A. F. *Nature* **1981**, 292, 756-762.
5. Nambiar, K. P., Stackhouse, J., Stauffer, D. M., Kennedy, W. P., Eldredge, J. K., Benner, S. A. *Science* **1984**, 223, 1299-1301.
6. Gibson, D. G., Benders, G.A., Andrews-Pfannkoch, C., *et al.* *Science* **2008**, 319, 1215-1220.
7. Benner, S. A. *Acc. Chem. Res.* **2004**, 37, 784-797
8. Benner, S. A., Yang, Z., Chen, F. *Comptes Rendus* **2011**, 14, 372-387